Novo Nordisk A/S (LON:0TDD)

Market Cap	125.99B -29.6%
Revenue (ttm)	37.94B +5.6%
Net Income	13.41B +4.8%
EPS	3.02 +5.0%
Shares Out	n/a
PE Ratio	9.39
Forward PE	11.83
Dividend	0.96 (3.39%)
Ex-Dividend Date	Aug 17, 2026

Volume	61,764
Open	37.97
Previous Close	38.23
Day's Range	37.43 - 38.17
52-Week Range	35.09 - 64.35
Beta	0.34
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 4, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 66,700
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0TDD

Financial Performance

In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.

Financial numbers in DKK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 2, 2026

Data Sources Report a data error